Paul J. Reider joined the faculty of Princeton University in 2008 where his research is focused on new drugs for Malaria, TB and other neglected diseases. During his 28 years in the pharmaceutical industry he has directly contributed to the discovery, identification, development or registration of 14 approved drugs: SINGULAIR, CRIXIVAN, PRIMAXIN, SUSTIVA/STOCRIN, INVANZ, COZAAR, AGGRASTAT, CANCIDAS, VIOXX, ARCOXIA, MAXALT, JANUVIA, EMEND and SENSIPAR.
From 2002-2007 he was at Amgen as Worldwide Head of Chemistry Research & Discovery. At Amgen he built and led a team of nearly 600 located in Thousand Oaks, San Francisco, Seattle, Cambridge (MA) and Regensburg, Germany.
He received his A.B. (Psychology) at New York University's Washington Square College and his Ph.D. (Organic Chemistry) at the University of Vermont. After post-doctoral research as an NIH National Research Service Awardee at Colorado State University, Paul joined Merck as a Senior Research Chemist in Process Chemistry where he remained for 22 years. Prior to joining Amgen, he was Vice President of Process Chemistry at Merck. Paul is an inventor on many patents, an author of more than 170 scientific papers, and the winner of numerous awards. Most recently, he was named the winner of the 2011 National Academy of Sciences' Award for Chemistry in Service to Society.
He's served on the visiting committees for Harvard University, California Institute of Technology, and the University of California, Santa Barbara, and on the Editorial Advisory Boards of the Journal of the American Chemical Society, the Journal of Organic Chemistry, and Organic Letters. He is also a Senior Editor of Current Opinion in Drug Discovery & Development, and Science of Synthesis. In 2011, Paul joined the Scientific Advisory Boards of the Medicines for Malaria Venture and the TB Alliance.